Close Menu

financial guidance

Alere rapid diagnostics revenues were $548 million in the quarter, driven by infectious disease and cardiometabolic testing product sales.

The firm also reaffirmed its previous guidance of 10 percent growth for fiscal 2019.

Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.


The firm's CEO told investors at the JP Morgan Healthcare Conference that in addition to driving growth of its sepsis test in the US, Accelerate is eyeing expansion into China.

The firm also posted full-year revenue growth of approximately 3 percent to $315 million, near the top end of its guidance of $310 million to $316 million and above analysts' consensus estimate.

The company also reaffirmed fiscal fourth quarter growth expectations including double-digit growth in the US for its TB testing products.

The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.

The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.

The company attributed the lower revenue growth to lower volume growth in diagnostics, which is expected to continue for the rest of the year.

For 2018, Quest lowered its revenues expectation to $7.57 billion, its EPS to greater than $5.34, and its adjusted EPS to greater than $6.30.

Pages